All In Biotech

Free tool

FAERS Monitor: Zypitamag

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208379 or its brand name (Zypitamag, Pitavastatin Magnesium). Reports on generic versions are filed under their own applications.

Reports

59

Serious

28

47% of reports

Hospitalization

11

Death reported

8

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • headache6
  • death5
  • dyspnoea5
  • hospitalisation5
  • product dose omission issue5
  • pruritus5
  • pain4
  • arthralgia3
  • cardiac death3
  • constipation3
  • dizziness3
  • fall3
  • fatigue3
  • malaise3
  • muscle spasms3

Reports by year received

View as table
YearReports
20182
20192
20205
20219
202222
20234
20244
20253
20268

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,100 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cardiac deathSignal3888.4294.61,841
hospitalisationSignal511.65.039
product dose omission issueSignal56.12.617
muscle spasmsSignal35.81.98
constipationSignal34.91.66
pruritusSignal54.62.011
headacheSignal63.41.68
fall33.21.13
dyspnoeaSignal53.11.45
arthralgia32.60.92
malaise32.40.81
pain42.30.92
dizziness32.10.71
death52.10.92
fatigue31.40.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.